Article
HLA-B*13:01 and the dapsone hypersensitivity syndrome.
The New England journal of medicine - 24 Oct 2013
Zhang F-R, Liu H, Irwanto A, Fu X-A, Li Y, Yu G-Q, Yu Y-X, Chen M-F, Low H-Q, Li J-H, Bao F-F, Foo J-N, Bei J-X, Jia X-M, Liu J, Liany H, Wang N, Niu G-Y, Wang Z-Z, Shi B-Q, Tian H-Q, Liu H-X, Ma S-S, Zhou Y, You J-B, Yang Q, Wang C, Chu T-S, Liu D-C, Yu X-L, Sun Y-H, Ning Y, Wei Z-H, Chen S-L, Chen X-C, Zhang Z-X, Liu Y-X, Pulit S L, Wu W-B, Zheng Z-Y, Yang R-D, Long H, Liu Z-S, Wang J-Q, Li M, Zhang L-H, Wang H, Wang L-M, Xiao P, Li J-L, Huang Z-M, Huang J-X, Li Z, Liu J, Xiong L, Yang J, Wang X-D, Yu D-B, Lu X-M, Zhou G-Z, Yan L-B, Shen J-P, Zhang G-C, Zeng Y-X, de Bakker P I W, Chen S-M, Liu J-J
Abstract excerpt
BACKGROUND: Dapsone is used in the treatment of infections and inflammatory diseases. The dapsone hypersensitivity syndrome, which is associated with a reported mortality of 9.9%, develops in about 0.5 to 3.6% of persons treated with the drug. Currently, no tests are available to predict the risk of the dapsone hypersensitivity syndrome. METHODS: We performed a genomewide association study involving 872...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
